ArticleFrontiers in cellular and infection microbiology2013
The use of resazurin as a novel antimicrobial agent against Francisella tularensis.
Article in Frontiers in cellular and infection microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 48 citations in OpenAlex.
- Counting cells can accurately predict small-molecule bioactivity benchmarks.Nature communications · 2026Article
- Preclinical activity of resazurin in acute myeloid leukaemia.British journal of haematology · 2025Article
- Phenotypic-Based Discovery and Exploration of a Resorufin Scaffold with Activity against Mycobacterium tuberculosis.ChemMedChem · 2024Article
- Antibacterial efficacy and membrane mechanism of action of theMicrobiology spectrum · 2024Article
- Low Oxygen Concentration ReducesAntibiotics (Basel, Switzerland) · 2024Article
- Antimicrobial properties of hindered amine light stabilizers in polymer coating materials and their mechanism of action.Frontiers in bioengineering and biotechnology · 2024Article
- Article
- Article
- The utilization of Blaptica dubia cockroaches as an in vivo model to test antibiotic efficacy.Scientific reports · 2021Article
- Role ofAntibiotics (Basel, Switzerland) · 2021Article
- Visible colorimetric growth indicators of Neisseria gonorrhoeae for low-cost diagnostic applications.PloS one · 2021Article
- Francisella novicida and F. philomiragia biofilm features conditionning fitness in spring water and in presence of antibiotics.PloS one · 2020Article
- A Review of Methods to Determine Viability, Vitality, and Metabolic Rates in Microbiology.Frontiers in microbiology · 2020Review
- Simple fluorometric-based assay of antibiotic effectiveness for Acinetobacter baumannii biofilms.Scientific reports · 2019Article
- The Anti-virulence Efficacy of 4-(1,3-Dimethyl-2,3-Dihydro-1H-Benzimidazol-2-yl)Phenol Against Methicillin-ResistantFrontiers in microbiology · 2019Article
- Antibacterial Properties of Four Novel Hit Compounds from a Methicillin-Resistant Staphylococcus aureus-Caenorhabditis elegans High-Throughput Screen.Microbial drug resistance (Larchmont, N.Y.) · 2018Article
- Repurposing the anthelmintic drug niclosamide to combat Helicobacter pylori.Scientific reports · 2018Article
- Benzoxazoles, Phthalazinones, and Arylurea-Based Compounds with IMP Dehydrogenase-Independent Antibacterial Activity against Francisella tularensis.Antimicrobial agents and chemotherapy · 2017Article
- Characterization of a Francisella tularensis-Caenorhabditis elegans Pathosystem for the Evaluation of Therapeutic Compounds.Antimicrobial agents and chemotherapy · 2017Article
- Activity of a novel protonophore against methicillin-resistant Staphylococcus aureus.Future medicinal chemistry · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The highly infectious and deadly pathogen, Francisella tularensis, is classified by the CDC as a Category A bioterrorism agent. Inhalation of a single bacterium results in an acute pneumonia with a 30-60% mortality rate without treatment. Due to the prevalence of antibiotic resistance, there is a strong need for new types of antibacterial drugs. Resazurin is commonly used to measure bacterial and eukaryotic cell viability through its reduction to the fluorescent product resorufin. When tested on various bacterial taxa at the recommended concentration of 44 μM, a potent bactericidal effect was observed against various Francisella and Neisseria species, including the human pathogens type A F. tularensis (Schu S4) and N. gonorrhoeae. As low as 4.4 μM resazurin was sufficient for a 10-fold reduction in F. tularensis growth. In broth culture, resazurin was reduced to resorufin by F. tularensis. Resorufin also suppressed the growth of F. tularensis suggesting that this compound is the biologically active form responsible for decreasing the viability of F. tularensis LVS bacteria. Replication of F. tularensis in primary human macrophages and non-phagocytic cells was abolished following treatment with 44 μM resazurin indicating this compound could be an effective therapy for tularemia in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.